Natixis Structured Issuance (X44335) Trades

Quantum Blockchain Technologies PLC (AIM:QBT) CEO Francesco Gardin takes Proactive's Stephen Gunnion through the company's latest business update, focusing on its Methods A and B. Gardin highlighted significant progress, including the acquisition of a crucial ASIC chip for Method B, which enables accurate performance testing. He explained the challenges of reverse engineering the BM1370 chip and the importance of obtaining source code for accurate testing. Regarding Method A, Gardin emphasised that real-world testing is ongoing to generate irrefutable data for potential partners. He also discussed the company's participation in the Mining Disrupt Bitcoin Mining Expo in Miami at the end of the month, where they plan to showcase a live demonstration. On the topic of previously signed NDAs with major Bitcoin industry players, Gardin noted that discussions are active, and a successful demo could open doors to further collaboration. He also addressed the ongoing legal case, confirming that despite an appeal, Quantum Blockchain is moving forward with asset recovery actions. For more insights into Quantum Blockchain Technologies' latest developments, watch the full interview. Don't forget to like, subscribe, and turn on notifications for more updates from Proactive. #QuantumBlockchain #BitcoinMining #ASICTechnology #BlockchainInnovation #CryptoTech #MiningDisrupt #CryptoNews #TechUpdate #Bitcoin #Blockchain

Solvonis Therapeutics PLC (LSE:SVNS) non-executive director-elect Dr Renata Crome talked with Proactive about her appointment to the board and what she brings to the company. Dr Crome has an extensive background in pharmaceutical development, having worked at Roche for 30 years. She played a key role in the development of blockbuster treatments such as bevacizumab and obinutuzumab for cancer, as well as Tamiflu for influenza. Following her time at Roche, she transitioned to board roles across commercial and charity organisations and also lectures in pharmaceutical medicine. Discussing her contributions to Solvonis, Dr Crome highlighted her strategic expertise and experience in central nervous system (CNS) treatments. "I have extensive experience in developing treatments in the central nervous system area, and I know the challenges and some of the solutions," she said. She also emphasised her ability to leverage a strong network of experts to support the company's goals. Dr Crome expressed enthusiasm for Solvonis' innovative pipeline and differentiated treatments, as well as the strength of its leadership team. "It’s a privilege to be invited to join them," she said. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for future content. #SolvonisTherapeutics #Pharmaceuticals #Biotech #HealthcareInnovation #Leadership #CNSResearch #DrugDevelopment #Investing #Biopharma #ExecutiveLeadership

Delivra Health Brands CEO Gord Davey joined Steve Darling from Proactive to announce the launch of Dream Water 6-Count Sleep Gummies in the Canadian market. This new product builds on the success of the 60-count Dream Water Gummies, which debuted in Canada in February 2024 and received strong consumer demand. The 6-count version is set to hit distributors, retailers, and e-commerce channels in March 2025. Davey highlighted that this strategic launch is aimed at capturing growth opportunities in the travel and convenience retail sectors, reinforcing Delivra Health’s position as a leading provider of sleep solutions. By offering a smaller, on-the-go format, the company aims to expand its reach to travelers and impulse buyers, broadening accessibility for consumers seeking convenient sleep aids. The momentum behind Dream Water Sleep Gummies continues to build in both Canada and the U.S., with the new 6-count format being distributed nationwide through Delivra Health’s established retail and e-commerce partners. With this expansion, the company is set to further strengthen its footprint in the sleep wellness market. #proactiveinveestors #delivrahealthbrandsinc #tsxv #dhb #otcqb #dhbuf #DreamWater #GlobalExpansion #UAE #MiddleEastMarket #SleepAid #HealthAndWellness #PharmacyProducts #RegulatoryCompliance #DreamWater #SleepGummies #Wellness #SleepAid #TravelEssentials #CanadianRetail #HealthAndWellness #InsomniaRelief #SleepBetter

TNR Gold Corp (TSX-V:TNR, OTC:TRRXF) executive chairman Kirill Klip talked with Proactive's Stephen Gunnion about the company’s latest developments, including a key milestone in its transition to a cash-flow-generating royalty business. Klip highlighted that TNR Gold holds royalties on significant projects, including the Los Azules Copper project and the Mariana Lithium project in Argentina. With Los Azules now applying for Argentina's incentive regime for large investments, he explained that the project could see substantial tax reductions, making it easier to attract the $2.7 billion investment required for construction. Discussing Argentina’s economic reforms under President Javier Milei, Klip noted that the country's policies are encouraging large-scale investment in the mining sector. He also pointed to the environmental permit secured for Los Azules, bringing it closer to a construction decision, with a feasibility study expected in the first half of the year. Klip also shared insights from Fundamental Research Corporation’s latest analysis, which increased its price target for TNR Gold from $0.24 to $0.28, underscoring the company's transition from a project generator to a cash-flow-generating royalty company. Watch the full interview for more insights into TNR Gold’s latest developments. For more interviews like this, subscribe to Proactive’s YouTube channel, give this video a like, and turn on notifications for future updates! #TNRGold #MiningInvesting #LosAzules #CopperMining #LithiumInvesting #MiningStocks #ArgentinaMining #RoyaltyCompany #StockMarket #JavierMilei